相关临床试验
275
37 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
13
4.7%
已完成
131
47.6%
Enrolling By Invitation
6
2.2%
尚未招募
18
6.5%
招募中
52
18.9%
终止
4
1.4%
Unknown
49
17.8%
撤回
2
0.7%
暂无批准数据
- Neoadjuvant radiotherapy followed by surgery improved 3-year overall survival to 88.5% compared to 85.2% with upfront surgery in locally advanced rectal cancer patients. - The treatment approach significantly increased pathologic complete response rates (22.4% vs 9.2%) and tumor downstaging compared to chemotherapy alone. - Radiotherapy was associated with higher rates of diverting stoma creation (65.5% vs 41.0%) and permanent stomas (20.6% vs 11.1%). - Benefits were most pronounced in lower rectal tumors and bad-risk patients, while upper rectal cancers showed minimal advantage from radiotherapy.
- Researchers identified the RASAL2 c.2423 A > G variant as a likely pathogenic germline mutation that enhances RAS signaling and promotes resistance to anti-EGFR therapy in colorectal cancer patients. - The variant was found in 1.63% of CRC patients compared to 0.4% in the general Taiwanese population, with no co-occurrence with KRAS mutations, suggesting mutual exclusivity. - Laboratory studies demonstrated that CRC cells harboring the RASAL2 variant required higher concentrations of cetuximab to suppress ERK phosphorylation and cell proliferation compared to wild-type cells. - The findings suggest RASAL2 c.2423 A > G could serve as a predictive biomarker for anti-EGFR therapy response and may warrant inclusion in hereditary cancer screening panels.
